WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009133963) METHODS OF ADMINISTERING ANTITUMOR AGENT COMPRISING DEOXYCYTIDINE DERIVATIVE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/133963    International Application No.:    PCT/JP2009/058725
Publication Date: 05.11.2009 International Filing Date: 28.04.2009
IPC:
A61K 31/7068 (2006.01), A61P 35/00 (2006.01)
Applicants: TAIHO PHARMACEUTICAL CO., LTD. [JP/JP]; 1-27, Kandanishiki-cho, Chiyoda-ku, Tokyo 1018444 (JP) (For All Designated States Except US).
SASAKI, Takuma [JP/JP]; (JP) (For All Designated States Except US).
MATSUDA, Akira [JP/JP]; (JP) (For All Designated States Except US).
OKABE, Hiroyuki [JP/JP]; (JP) (For US Only).
ARAKAWA, Kazuhito [JP/JP]; (JP) (For US Only)
Inventors: OKABE, Hiroyuki; (JP).
ARAKAWA, Kazuhito; (JP)
Agent: THE PATENT CORPORATE BODY ARUGA PATENT OFFICE; Kyodo Bldg. 3-6, Nihonbashiningyocho 1-chome Chuo-ku, Tokyo 1030013 (JP)
Priority Data:
12/111,369 29.04.2008 US
Title (EN) METHODS OF ADMINISTERING ANTITUMOR AGENT COMPRISING DEOXYCYTIDINE DERIVATIVE
(FR) PROCÉDÉS D'ADMINISTRATION D'UN AGENT ANTICANCÉREUX COMPORTANT UN DÉRIVÉ DE DÉSOXYCYTIDINE
Abstract: front page image
(EN)Antitumor treatment regimens comprising: administering, to a patient diagnosed with cancer, an antitumor agent comprising 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone, or a salt thereof, by way of continuous intravenous infusion, in an amount of 2.0 to 4.0 mg per m2 total body surface area of the patient, of 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent, per day, for a duration of 168 to 336 hours. Compositions for providing the methods are also disclosed.
(FR)L'invention porte sur des régimes de traitement anticancéreux qui comportent : l'administration, à un patient pour lequel on a diagnostiqué un cancer, d'un agent anticancéreux comportant la 4-amino-1-(2-cyano-2-désoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone, ou un sel de celle-ci, au moyen d'une perfusion intraveineuse continue, en une quantité de 2,0 à 4,0 mg par m² d'aire de surface corporelle totale du patient, d'un équivalent de la 4-amino-1-(2-cyano-2-désoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone, par jour, pour une durée de 168 à 336 heures. L'invention porte également sur des compositions pour la mise en œuvre des procédés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)